Synexus

What Synexus does

Synexus, founded in 1992 and headquartered in Chorley, United Kingdom, is a private clinical trials site network organization operating more than 250 clinical sites across at least eight countries including the United Kingdom, United States, South Africa, Bulgaria, the Czech Republic, Germany, Hungary and Poland. The company provides integrated site services to pharmaceutical sponsors and contract research organizations (CROs), supporting participant identification and engagement, pre-screening, study planning, early-phase trials and home trial services, with stated coverage across biosimilars, cardiovascular, dermatology, metabolic, neurology, respiratory and vaccine studies.

Synexus has scaled primarily through acquisition, completing at least six disclosed site acquisitions between 2006 and 2016 (including Skandynawskie Centrum Medyczne in 2006, Diagnostic Units Hungary in 2006, ClinPharm International in 2009, Osteomed Sp. z o.o in 2012, Helderberg Clinical Research Centre in South Africa in 2014 and Research Across America in 2016 in the United States). The company reports a 20 million identified-participant database and 4,700+ recruited studies across more than 40 years of clinical experience, which constitute its principal recruitment and operational assets.

The business model is a B2B services model in which sponsors and CROs contract with Synexus for access to its site network, with associated patient recruitment, retention, data quality and oversight deliverables. The company appears to operate under the Trialmed brand on its public-facing sites (including a UK site under synexusclinic.co.uk and a US site under trialmed.com), and references a thermofisher.com privacy policy, suggesting integration with or ownership by the Thermo Fisher/PPD ecosystem. No pricing model, revenue figure, or detailed ownership structure is disclosed in the source data, which is a material gap for any commercial analysis.

Name

Synexus

Legal name

Synexus

Website

https://synexusclinic.co.uk

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Synexus is a UK-founded, private clinical trials site network operating 250+ sites across eight countries, providing integrated site services, patient recruitment, early-phase and home trial services to pharmaceutical sponsors and CROs across multiple therapy areas.

Ownership category

akta.pro rank

Product category

Clinical Trial Site Services

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Clinical trial site network
• Patient recruitment services
• Site management organization
• Clinical research services
• Clinical study management

Headquarters

HQ city

Chorley

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D

Core offering

Synexus operates a global clinical trial site network providing site management, patient recruitment, and integrated clinical research services to pharmaceutical sponsors and CROs. The organization runs 250+ dedicated clinical trial sites across multiple countries, recruiting from a 20 million identified-participant database to execute studies across therapy areas including cardiovascular, dermatology, metabolic, neurology, respiratory, vaccines, and biosimilars, including early-phase and home-based trial formats.

Product overview

Synexus offers a context analysis approach for digital ad placement safety and effectiveness. Their research highlights the inefficiencies of traditional keyword-blocking ad-tech tools and positions their contextual analysis solution as an alternative approach to improve ad placement decisions. The company has released a study demonstrating that ads placed next to polarizing content perform 25% worse with higher negative brand perceptions.

Differentiator

Problem solved

Functional benefit

Products and services

• Integrated Site Services A bundle of site management services delivered through Synexus's global clinical trial site network for pharmaceutical sponsors and CROs, including global reach, flexible site models, dedicated research teams, and early-phase clinical trial capabilities.
• Patient Identification and Engagement Recruitment service that leverages Synexus's 20 million identified-participant database to identify, screen, and enroll eligible patients into sponsor-led clinical trials.
• Pre-Screening Services Clinical pre-screening service that assesses potential participants against protocol inclusion/exclusion criteria prior to enrollment in sponsor clinical trials.
• Study Planning Pre-award study planning service that supports sponsors and CROs in designing feasible clinical trial protocols, site selection, and resource planning across the Synexus network.
• Home Trial Services Decentralized clinical trial service enabling study visits and procedures to be conducted at participants' homes or remote locations rather than central sites, supporting sponsors' hybrid and decentralized trial strategies.
• Cardiovascular Clinical Trials Therapy-area clinical trial services in cardiovascular indications (e.g., heart failure, hypertension), delivered through dedicated Synexus sites for pharmaceutical and CRO sponsors.
• Dermatology Clinical Trials Therapy-area clinical trial services in dermatology indications, delivered through Synexus sites for pharmaceutical and CRO sponsors.
• Metabolic Clinical Trials Therapy-area clinical trial services in metabolic indications (including obesity), delivered through Synexus sites for pharmaceutical and CRO sponsors.
• Neurology Clinical Trials Therapy-area clinical trial services in neurology indications, delivered through Synexus sites for pharmaceutical and CRO sponsors.
• Respiratory Clinical Trials Therapy-area clinical trial services in respiratory indications (including asthma), delivered through Synexus sites for pharmaceutical and CRO sponsors.
• Vaccine Clinical Trials Therapy-area clinical trial services in vaccine indications, including studies in adults aged 65+ at increased risk of infection, delivered through Synexus sites for pharmaceutical and CRO sponsors.
• Biosimilars Clinical Trials Therapy-area clinical trial services in biosimilars, delivered through Synexus sites for pharmaceutical and CRO sponsors developing biosimilar products.
• Early-Phase Clinical Trials Early-phase (Phase I and early clinical development) trial services delivered through dedicated Synexus research teams and sites for pharmaceutical and CRO sponsors.

Quantifiable outcome

• 25% less attention when ads placed next to polarizing content

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IQVIA: Largest global CRO with a dedicated site network (IQVIA Site Management) and integrated clinical operations; competes with Trialmed/Synexus for Phase II–III site services and patient recruitment, particularly with large pharma sponsors.
• ICON plc: Global CRO formed via the PRA Health Sciences merger, with extensive site management and dedicated clinical research units; directly comparable in providing full-service and dedicated-site clinical trial delivery.
• Thermo Fisher Scientific (PPD): Parent of Trialmed/Synexus post-PPD acquisition; PPD operates a global clinical research services platform with early-phase sites and bioanalytical labs, comparable as a full-service CRO with embedded site operations.
• Parexel International: Large global CRO with broad Phase I–IV capabilities including site feasibility, patient recruitment, and dedicated clinical operations; comparable as a full-service clinical research services provider.
• Charles River Laboratories: Global CRO/CDMO with a clinical services arm (after the PPD and WuXi AppTec acquisitions/divestitures), providing clinical trial site services and central lab testing; comparable in site operations and clinical research services.

Direct peers

• Medpace: Mid-sized global CRO operating investigator sites across multiple therapeutic areas with strong site operations and patient recruitment; most direct comparably-sized competitor for Trialmed's dedicated site and full-service model.
• Syneos Health: Biopharma solutions organization combining CRO and clinical site services (formerly inVentiv/Syncor), with significant site network exposure and contract resourcing comparable to Trialmed/Synexus's hybrid model.
• Worldwide Clinical Trials: Mid-sized global CRO with strong site management and therapeutic-area expertise in CNS, cardiometabolic, and rare disease; competes head-to-head with Trialmed for sponsor awards requiring dedicated site infrastructure.
• Pharm-Olam International: Mid-sized CRO/SMO hybrid focused on oncology, infectious disease, and rare disease trials; comparable to Trialmed in operating dedicated investigator sites with full-service delivery capability.

Emerging players

• Caidya (formerly Clinipace Worldwide): Mid-sized global CRO/SMO hybrid with dedicated site services and a technology-enabled trial platform; comparable to Trialmed as a smaller, multi-therapeutic site-and-CRO competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/synexusresearch
• Facebookfacebook.com/synexusuk
• LinkedInlinkedin.com/company/synexus

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synexus